Risk factors for voriconazole-associated hepatotoxicity in patients with liver dysfunction: a retrospective nested case–control study
The incidence of voriconazole-induced ALI was higher in patients with mild or moderate liver dysfunction than in the general population. Trough VPC and voriconazole treatment duration are two independent risk factors of ALI. Therefore, voriconazole should be administered with caution to these patients. A lower target trough VPC (<3.81 mg/L) is recommended to minimize the risk of ALI in patients with mild-to-moderate liver dysfunction.
Authors
- Jinlin Guo (ORCID: https://orcid.org/0000-0001-9091-7100)
- Wei Ge (ORCID: https://orcid.org/0000-0001-5962-1520)
- Xinfeng Cai (ORCID: https://orcid.org/0000-0003-0809-7102)
- Shan Wang (ORCID: https://orcid.org/0009-0009-6450-7488)
- Le Yang (ORCID: https://orcid.org/0009-0002-1999-4503)
- Jing Ren (ORCID: https://orcid.org/0009-0000-5330-5383)
- Linna Liu
- Qinhui Wang (ORCID: https://orcid.org/0000-0002-1796-0679)
- Qi Yang (ORCID: https://orcid.org/0009-0001-3329-5189)
Institutions
- Long Island University (US)
- Shanxi Provincial Cancer Hospital (CN)
- Island Hospital (US)
- Tang Du Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.3389/fphar.2025.1625003
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00